|CBI -- Israel Stock|| |
ILS 341.80 1.30 0.38%
We currently do not have informatin regarding Orit Lidor. This executive tanure with Clal Biotechnology Industries Ltd is not currenlty determined.
Age: 35 VP Since 2011
972 3 612 1616 http://www.cbi.co.il
The company has return on total asset (ROA)
of (4.59) %
which means that it has lost $4.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (2.14) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 85.39 M in total debt with debt to equity ratio (D/E) of 10.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology Industries Ltd has Current Ratio of 3.35 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. Clal Biotechnology operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange.Clal Biotechnology Industries Ltd (CBI) is traded on Tel Aviv Stock Exchange in Israel. It is located in Azrieli Center and employs 14 people.
Clal Biotechnology Leadership Team
|Ofer Goldberg, VP|
|Sigalia Heifetz, Director|
|Shmuel Rubinstein, External Director|
|Tomer Babai, Director|
|Dafna Gruber, Director|
|Aharon Schwartz, Director|
|Gavriel Barabash, Director|
|Isaac Kohlberg, Director|
|Nofar Malovani, Director|
|Assaf Segal, CFO|
|Ofer Gonen, Vice President|
|Avraham Fischer, Chairman of the Board|
|Yuval Yanai, External Director|
|Julian Adams, President Chief Scientific Officer|
|Orit Lidor, VP and General Counsel|
Stock Performance Indicators